GlassScriptPhysician profile
Janice M Moore
NPI 1588653307
$4,037.94
in general payments reported to CMS, 2019-2025
21 companies · $2,246 in 2025
The $2,246 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $684 · 2022: $481 · 2023: $190 · 2024: $436 · 2025: $2,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,474 · Food and Beverage: $1,111 · Travel and Lodging: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,474.00 |
| Food and Beverage | $1,110.50 |
| Travel and Lodging | $288.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $2,176.58 | 2024-2025 | Envarsus |
| Abbvie INC. | $315.94 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $268.11 | 2021-2023 | |
| Pfizer INC. | $158.31 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $123.12 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $122.19 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $121.77 | 2024 | Breztri |
| Agile Therapeutics, INC. | $117.41 | 2021 | |
| Mallinckrodt Hospital Products INC. | $102.19 | 2024 | Terlivaz |
| Otsuka America Pharmaceutical, INC. | $90.71 | 2022 | |
| Mylan Pharmaceuticals INC. | $86.12 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $61.20 | 2021 | |
| Exeltis, USA INC. | $60.60 | 2022-2023 | Slynd |
| Therapeuticsmd, INC. | $49.52 | 2021 | |
| Organon LLC | $40.82 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $38.17 | 2022 | |
| Novo Nordisk INC | $27.88 | 2021 | |
| Hologic Sales and Service, LLC | $24.99 | 2023 | Acessa Provu System, Myosure Tissue Removal Device |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.26 | 2024 | Xifaxan |
| Gilead Sciences, INC. | $17.19 | 2024 | |
| Axonics, INC. | $15.86 | 2023 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.